From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD

STAT News

Biotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry. ...

전문 보기

이 뉴스, 어떠셨어요?

탭 한 번으로 반응 · 로그인 불필요

관련 뉴스

관련 뉴스 제보는 로그인 후 가능합니다.

'science' 카테고리 뉴스

Similarity between human and bovine cells could advance drug discovery

Phys.org

Self-cleaning nanoscale sensor could transform personalized medicine

Phys.org

Cyclosporiasis sickens some people worse—why your diarrhea could be more explosive than others

Medical Xpress

STAT의 다른 기사

STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials

STAT News

STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment

STAT News

STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more

STAT News